Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02079766 · ClinicalTrials.gov registry record · Phase 2
18F-AV-1451 and Florbetapir F 18 PET (Positron Emission Tomography) Imaging in Subjects at Risk for Chronic Traumatic Encephalopathy
A Phase 2 study of Chronic Traumatic Encephalopathy, sponsored by Avid Radiopharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
- 2
- Study locations
NCT02079766 is a Phase 2 study of Chronic Traumatic Encephalopathy that has completed, run by Avid Radiopharmaceuticals. The registered enrollment target is 41 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT02079766, a Phase 2 study of Chronic Traumatic Encephalopathy, has completed, sponsored by Avid Radiopharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study will explore the use of flortaucipir as a biomarker for chronic traumatic encephalopathy (CTE) and examine the relationship between clinical presentation and tau deposition.
Conditions Studied
Interventions
- DRUG Flortaucipir F18
- DRUG florbetapir F 18
Study Locations (2)
Arizona
- Banner Alzheimer's Institute - Phoenix
Massachusetts
- Boston University - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2014-06 |
| Est. Completion | 2015-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02079766
The ClinicalTrials.gov registry entry for NCT02079766 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Avid Radiopharmaceuticals, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Traumatic Encephalopathy appearing as the primary indexed condition, and to 2 interventions - of which Flortaucipir F18 is the first listed.
NCT02079766 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Arizona, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02079766 about?
NCT02079766 is a clinical study titled "18F-AV-1451 and Florbetapir F 18 PET (Positron Emission Tomography) Imaging in Subjects at Risk for Chronic Traumatic Encephalopathy". This study will explore the use of flortaucipir as a biomarker for chronic traumatic encephalopathy (CTE) and examine the relationship between clinical presentation and tau deposition.
What is the current status of trial NCT02079766?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2014-06. Estimated completion is 2015-10.
What conditions does trial NCT02079766 study?
This clinical trial studies the following conditions: Chronic Traumatic Encephalopathy.
What interventions are being tested in trial NCT02079766?
The interventions under investigation include: Flortaucipir F18 (DRUG), florbetapir F 18 (DRUG).
Who is sponsoring clinical trial NCT02079766?
This trial is sponsored by Avid Radiopharmaceuticals, which has 42 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02079766 being conducted?
This trial has 2 study locations across Arizona, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Traumatic Encephalopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.